NCT02495779View on ClinicalTrials.gov

Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV

NACompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

emtricitabine/tenofovir

Short-term episodic use for 2-3 weeks.

BEHAVIORAL

CBT-based counseling

Brief CBT-based counseling to promote adherence

Trial Locations (2)

15213

Div of Infectious Diseases, University of Pittsburgh, Pittsburgh

02215

The Fenway Institute, Boston

All Listed Sponsors
collaborator

Fenway Community Health

OTHER

collaborator

National Institute of Mental Health (NIMH)

NIH

lead

James Egan

OTHER

NCT02495779 - Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV | Biotech Hunter | Biotech Hunter